Prof. Dr. GÜRSEL BİBEROĞLU

Kişisel Bilgiler

İş Telefonu: +90 312 202 5468
E-posta: gurselb@gazi.edu.tr
Web: https://avesis.gazi.edu.tr/gurselb

Uluslararası Araştırmacı ID'leri
ScholarID: L7Ff4cUAAAAJ
ORCID: 0000-0001-9469-993X
ScopusID: 6603282821
Yoksis Araştırmacı ID: 51650

Eğitim Bilgileri

Doktora, Erciyes Üniversitesi, Sağlık Bilimleri Enstitüsü, Biyokimya (Dr), Türkiye 1988 - 1991
Tıpta Uzmanlık, Erciyes Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Türkiye 1984 - 1987
Lisans, Ankara Üniversitesi, Eczacılık Fakültesi, Eczacılık Pr., Türkiye 1978 - 1982

Yabancı Diller

İngilizce, B2 Orta Üstü

Yaptığı Tezler

Doktora, Behçet hastalarında antioksidan mekanizma, Erciyes Üniversitesi, Siyasi Tarih, Biyokimya (Dr), 1991

Araştırma Alanları

Sağlık Bilimleri

Akademik Unvanlar / Görevler

Prof. Dr., Gazi Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri, 1991 - Devam Ediyor

Yönetilen Tezler

BİBEROĞLU G., Pediatrik renal transplant ve kronik böbrek yetmezliği hastalarında aterosklerotik risk faktörleri, Tıpta Uzmanlık, O.BALCI(Öğrenci), 2008

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

I. **Evaluation of Lysosphingolipid Analysis for the Diagnosis of Lysosomal Storage Disease**
Civelek-Urey B., Kasapkara C. S., BİBEROĞLU G., Oktem R. M., Gunduz M., Kireker-Koylu O., Yurek B., Gurbuz B. B., Tumer L.
KLINISCHE PADIATRIE, 2024 (SCI-Expanded)

II. **Clinical and Radiological Profile of Nine Patients with Metachromatic Leukodystrophy**
Kasapkara C. S., Urey B. C., Gurbuz B. B., Yavas A. K., Keceli A. M., Oncul U., Gunduz M., BİBEROĞLU G., Kurt A. N. C., Gurkas E., et al.
MOLECULAR SYNDROMOLOGY, 2024 (SCI-Expanded)

III. **Endocrinological and metabolic profile of Gaucher disease patients treated with enzyme replacement therapy**
KILIÇ A., Emecen Sanli M., Ozsaydl Aktasoglu E., GÖKALP S., BİBEROĞLU G., Inci A., OKUR İ., EZGÜ F. S., TÜMER L.
Journal of Pediatric Endocrinology and Metabolism, cilt.37, sa.5, ss.413-418, 2024 (SCI-Expanded)

IV. **Is lysosomal acid lipase activity associated with the presence and severity of coronary artery disease? Steht die Aktivität der lysosomalen sauren Lipase in Zusammenhang mit dem Vorliegen und dem Schweregrad einer koronaren Herzkrankheit?**
Kızıltunç E., Gökalp S., Biberoğlu G., Yalçın Y., Cihan B., Öktem R. M., İnci A., Tümer L., Yalçın M. R., Abacı A.
Herz, cilt.49, sa.1, ss.75-80, 2024 (SCI-Expanded)

V. **Pterin Profiling in Serum, Dried Blood Spot, and Urine Samples Using LC-MS/MS in Patients with Inherited Hyperphenylalaninemia**
Öktem R. M., İnci A., BAYRAK H., DEMİR F., BİBEROĞLU G., Maviş M. E., Gürsu G. G., Yllmaz H., OKUR İ., EZGÜ F. S., et al.
Molecular Syndromology, cilt.15, sa.3, ss.185-193, 2024 (SCI-Expanded)

VI. **Diagnostic value of plasma lysosphingolipids levels in a Niemann-Pick disease type C patient with transient neonatal cholestasis**
Bulut F. D., Bozbulut N. E., Ozalp O., DALGIÇ B., Mungan N. O., Ucar H. K., BİBEROĞLU G.
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, cilt.35, ss.681-685, 2022 (SCI-Expanded)

VII. **Combination of the histone deacetylase inhibitor valproic acid and stopcodon readthrough therapy produces improved alpha-galactosidase activity in Fabry patient-derived R227X fibroblasts**
Dundar H., BİBEROĞLU G., İNCİ A., OKUR İ., Tumer L., Ezgu F.
EUROPEAN JOURNAL OF HUMAN GENETICS, cilt.30, sa.SUPPL 1, ss.558, 2022 (SCI-Expanded)

VIII. **An ultra-rare cause of severe hypotonia mimicking Pompe disease in an infant: RRM2B related mitochon- drial DNA depletion syndrome with a novel mutation**
İNCİ A., OKUR İ., DEMİR E., BİBEROĞLU G., TÜMER L., SERDAROĞLU A., EZGÜ F. S.
NEUROLOGY ASIA, cilt.27, sa.1, ss.199-202, 2022 (SCI-Expanded)

IX. **Synergistic action of the chemical chaperone 4-phenylbutyrate and the pharmacological chaperone migalastat on restoration of alpha-galactosidase activity of Fabry G258R mutation**
DÜNDAR H., BİBEROĞLU G., İNCİ A., OKUR İ., TÜMER L., EZGÜ F. S.
MOLECULAR GENETICS AND METABOLISM, cilt.135, sa.2, 2022 (SCI-Expanded)

X. **The first case with FBXL4 mutation successfully treated with a parenteral ketogenic diet for lactic acidosis**
İNCİ A., Aktas E., Cengiz Ergin F. B., OKUR İ., BİBEROĞLU G., EZGÜ F. S., TÜMER L.
JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, cilt.45, sa.8, ss.1788-1792, 2021 (SCI-Expanded)

XI. **Congenital defects of glycosylation: Novel presentations with mainly neurological involvement and variable dysmorphic features**
İNCİ A., Cengiz B., BİBEROĞLU G., OKUR İ., ARHAN E., ÖNER A. Y., KASAPKARA Ç. S., Kucukcongar A., TÜMER L., Ezgu F. S.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, cilt.185, sa.9, ss.2739-2747, 2021 (SCI-Expanded)

XII. **Ultra-Rare Disorder in a Young Girl with Lipodystrophy: Analbuminemia**
İNCİ A., Arslan B., OKUR İ., BİBEROĞLU G., ŞANLI M. E., ÖZSAYDI AKTAŞOĞLU E., KILIÇ A., TÜMER L., EZGÜ F. S.
INDIAN JOURNAL OF PEDIATRICS, cilt.88, ss.723-0, 2021 (SCI-Expanded)

XIII. **A CASE OF GLYCOGEN STORAGE DISEASE TYPE 1a MIMICKING FAMILIAL CHYLOMICRONEMIA**

SYNDROME
Olgac A., OKUR İ., BİBEROĞLU G., EZGÜ F. S., TÜMER L.
BALKAN JOURNAL OF MEDICAL GENETICS, cilt.24, sa.1, ss.103-105, 2021 (SCI-Expanded)

XIV. **Autism: Screening of inborn errors of metabolism and unexpected results**
İnci A., Özaslan A., Okur İ., Biberoğlu G., Güney E., Ezgü F. S., Tümer L., İşeri E.
AUTISM RESEARCH, cilt.14, sa.5, ss.887-896, 2021 (SCI-Expanded)

XV. **The chemical chaperone 4-phenylbutyrate enhances alpha-galactosidase activity subsequent to stop-codon read-through therapy with triamterene in Fabry R227X fibroblasts**
Dündar H., Biberoğlu G., İnci A., Işık Gönül İ., Okur İ., Tümer L., Ezgü F. S.
MOLECULAR GENETICS AND METABOLISM, cilt.132, sa.2, 2021 (SCI-Expanded)

XVI. **Two patients from Turkey with a novel variant in the GM2A gene and review of the literature**
İNCİ A., ERGİN F. B., BİBEROĞLU G., OKUR İ., EZGÜ F. S., TÜMER L.
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, cilt.34, sa.6, ss.805-812, 2021 (SCI-Expanded)

XVII. **A rare urea cycle disorder in a neonate: N-acetylglutamate synthetase deficiency**
Olgac A., Kasapkara C. S., Kilic M., Derinkuyu B. E., Azapagasi E., Kesici S., BİBEROĞLU G., Ozyazici A., Karaca M., Haberle J.
ARCHIVOS ARGENTINOS DE PEDIATRIA, cilt.118, sa.6, 2020 (SCI-Expanded)

XVIII. **Beneficial Effects of Modified Atkins Diet in Glycogen Storage Disease Type IIIa**
Olgac A., İNCİ A., OKUR İ., BİBEROĞLU G., Oguz D., EZGÜ F. S., Kasapkara C. S., Aktas E., TÜMER L.
ANNALS OF NUTRITION AND METABOLISM, cilt.76, sa.4, ss.233-241, 2020 (SCI-Expanded)

XIX. **Vitamin D Levels and Bone Mineral Density in Inborn Errors of Metabolism Requiring Specialised Diets**
Olgac A., İNCİ A., OKUR İ., Ezgu F. S., BİBEROĞLU G., Turner L.
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, cilt.29, sa.12, ss.1207-1211, 2019 (SCI-Expanded)

XX. **A possible biomarker of neurocytolysis in infantile gangliosidoses: aspartate transaminase**
Kilic M., Kasapkara C. S., Kilavuz S., Mungan N. O., BİBEROĞLU G.
METABOLIC BRAIN DISEASE, cilt.34, sa.2, ss.495-503, 2019 (SCI-Expanded)

XXI. **High incidence of co-existing factors significantly modifying the phenotype in patients with Fabry disease.**
Koca S., TÜMER L., OKUR İ., ERTEN Y., Bakkaloglu S. A., BİBEROĞLU G., Kasapkara C., Kucukcongar A., DALGIÇ B., ÖZHAN OKTAR S., et al.
Gene, cilt.687, ss.280-288, 2019 (SCI-Expanded)

XXII. **Neonatal multiple sulfatase deficiency with a novel mutation and review of the literature**
NUR B., MIHÇI E., Pepe S., BİBEROĞLU G., EZGÜ F. S., Ballabio A., Oztekin O., DURSUN O.
TURKISH JOURNAL OF PEDIATRICS, cilt.56, sa.4, ss.418-422, 2014 (SCI-Expanded)

XXIII. **Vitamin A status and factors associated in healthy school-age children**
VURALLI KARAOĞLAN D., TÜMER L., Hasanoglu A., BİBEROĞLU G., PAŞAOĞLU H.
CLINICAL NUTRITION, cilt.33, sa.3, ss.509-512, 2014 (SCI-Expanded)

XXIV. **Could GSD type I expand the spectrum of disorders with elevated plasma chitotriosidase activity?**
TÜMER L., Kasapkara C. S., BİBEROĞLU G., Ezgu F. S., Hasanoglu A.
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, cilt.26, sa.11-12, ss.1149-1152, 2013 (SCI-Expanded)

XXV. **Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: Identification of new case with novel mutation**
OKUR İ., Ezgu F. S., BİBEROĞLU G., Turner L., ERTEN Y., Isitman M., Eminoglu F. T., Hasanoglu A.
GENE, cilt.527, sa.1, ss.42-47, 2013 (SCI-Expanded)

XXVI. **Asymmetric dimethylarginine (ADMA) and L-arginine levels in children with glycogen storage disease type I**
Kasapkara C. S., TÜMER L., BİBEROĞLU G., Kasapkara A., Hasanoglu A.
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, cilt.26, ss.427-431, 2013 (SCI-Expanded)

XXVII. **Assessment of atherosclerosis risk due to the homocysteine-asymmetric dimethylarginine-nitric**

oxide cascade in children taking antiepileptic drugs
Emeksiz H. C., SERDAROĞLU A., BİBEROĞLU G., GÜLBAHAR Ö., ARHAN E., CANSU A., Arga M., Hasanoglu A.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, cilt.22, sa.2, ss.124-127, 2013 (SCI-Expanded)

XXVIII. **The effect of zinc on ethanol-induced oxidative stress in rat liver**
Caglar O. M., Bilgihan A., ÖZEL TÜRKCÜ Ü., BİBEROĞLU G., TAKE KAPLANOĞLU G.
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, cilt.37, sa.4, ss.437-444, 2012 (SCI-Expanded)

XXIX. **Analysis of acylcarnitine levels by tandem mass spectrometry in epileptic children receiving valproate and oxcarbazepine**
Cansu A., Serdaroğlu A., Biberoğlu G., Tümer L., Hırfanoğlu T., Ezgü F. S., Hasanoglu A.
EPILEPTIC DISORDERS, cilt.13, sa.4, ss.394-400, 2011 (SCI-Expanded)

XXX. **The levels of asymmetric dimethylarginine, homocysteine and carotid intima-media thickness in hypercholesterolemic children**
Hasanoglu A., OKUR İ., Oren A. C., BİBEROĞLU G., ÖZHAN OKTAR S., Eminoglu F. T., TÜMER L.
TURKISH JOURNAL OF PEDIATRICS, cilt.53, sa.5, ss.522-527, 2011 (SCI-Expanded)

XXXI. **Very long-chain acyl CoA dehydrogenase deficiency which was accepted as infanticide**
Eminoglu T. F., TÜMER L., OKUR İ., EZGÜ F. S., BİBEROĞLU G., Hasanoglu A.
FORENSIC SCIENCE INTERNATIONAL, cilt.210, 2011 (SCI-Expanded)

XXXII. **N-carbamylglutamate treatment for acute neonatal hyperammonemia in isovaleric acidemia**
Kasapkara C. S., EZGÜ F. S., OKUR İ., TÜMER L., BİBEROĞLU G., Hasanoglu A.
EUROPEAN JOURNAL OF PEDIATRICS, cilt.170, sa.6, ss.799-801, 2011 (SCI-Expanded)

XXXIII. **Carnosine supplementation protects rat brain tissue against ethanol-induced oxidative stress**
ÖZEL TÜRKCÜ Ü., Bilgihan A., BİBEROĞLU G., Caglar O. M.
MOLECULAR AND CELLULAR BIOCHEMISTRY, cilt.339, ss.55-61, 2010 (SCI-Expanded)

XXXIV. **3-Methylcrotonyl-CoA Carboxylase Deficiency: Phenotypic Variability in a Family**
Eminoglu F. T., Ozcelik A. A., OKUR İ., TÜMER L., BİBEROĞLU G., DEMİR E., Hasanoglu A., Baumgartner M. R.
JOURNAL OF CHILD NEUROLOGY, cilt.24, sa.4, ss.478-481, 2009 (SCI-Expanded)

XXXV. **Asymmetric dimethylarginine and coronary collateral vessel development**
Kocaman S. A., ŞAHİNARSLAN A., BİBEROĞLU G., Hasanoglu A., Akyel A., Timurkaynak T., Cengel A.
CORONARY ARTERY DISEASE, cilt.19, sa.7, ss.469-474, 2008 (SCI-Expanded)

XXXVI. **Asymmetrical dimethylarginine level in atrial fibrillation**
Cengel A., ŞAHİNARSLAN A., BİBEROĞLU G., Hasanoglu A., Tavil Y., Tulmac M., Ozdemir M.
ACTA CARDIOLOGICA, cilt.63, sa.1, ss.33-37, 2008 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler

I. **Simultaneous succinylacetone-nitisinone measurement in tyrosinemia type I patients and evaluation of the nitisinone therapeutic range**
Öktem R. M., İnci A., Biberoğlu G., Okur İ., Ezgü F. S., Tümer L.
Biochimica Clinica, cilt.47, sa.3, ss.340-345, 2023 (Scopus)

II. **MİTOKONDRİYAL HASTALIK NEDENİYLE TETKİK EDİLEN HASTALARDA M.16189T>C DEĞİŞİKLİĞİNİN METABOLİK SENDROM AÇISINDAN İNCELENMESİ**
İNCİ A., Hasanoğlu A., OKUR İ., BİBEROĞLU G., TÜMER L., EZGÜ F. S.
Kocatepe Tıp Dergisi, cilt.23, sa.3, ss.322-325, 2022 (Hakemli Dergi)

III. **m.3010G>A Değişikliğinin Türk Populasyonunda Siklik Kusma Sendromuna Etkisi**
ERGİN F. B., İNCİ A., OKUR İ., BİBEROĞLU G., TÜMER L., EZGÜ F. S.
Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, 2022 (Hakemli Dergi)

IV. **PROPIONYLCARNITINE AND FREE CARNITINE ARE NEW BIOMARKERS IN THE FOLLOW-UP PERIOD OF MUCOPOLYSACCARIDOSIS TO SCREEN OXIDATIVE STRESS**
İNCİ A., OLGAÇ A., GENÇ DERİN B., BİBEROĞLU G., OKUR İ., EZGÜ F. S., TÜMER L.
Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi, cilt.28, sa.4, ss.565-571, 2021 (Hakemli Dergi)

V. **Do cytokines play role in the pathogenesis of mucopolysaccharidosis**
İNCİ A., OLGAÇ KILIÇKAYA M. A. B., YILMAZ DEMİRTAŞ C., OKUR İ., BİBEROĞLU G., EZGÜ F. S., TÜMER L.
Medicine Science, cilt.10, sa.4, ss.1492-1497, 2021 (Hakemli Dergi)

VI. **The Relationship between Inflammation and Serum Estrogen, Testosterone, and DHEA-S Levels in Obstructive Coronary Artery Disease**
Karaaslan O. C., ÜNLÜ S., TOPAL S., BİBEROĞLU G., Biberoglu K., ÇENGEL A.
GAZI MEDICAL JOURNAL, cilt.32, sa.2, ss.171-173, 2021 (ESCI)

VII. **"Double Hit" Homozygous Mutations for Two Different Rare Inborn Errors of Metabolism: A Burden for Countries with High Prevalences of Consangineous Marriages**
Olgac A., TÜMER L., Ceylaner S., BİBEROĞLU G., Hasanoglu A.
JOURNAL OF PEDIATRIC RESEARCH, cilt.5, sa.1, ss.47-50, 2018 (ESCI)

VIII. **L carnitine L propionyl carnitine and malondialdehyde levels of pediatric patients with solid tumor**
OKUR A., HASANOĞLU A., OĞUZ A., BİBEROĞLU G., ERTEM U., TÜMER L.
JOURNAL OF PEDİATRİC SCİENCES, cilt.4, sa.3, 2012 (Hakemli Dergi)

IX. **Analysis Of Acylcarnitine Profiles In Children With Idiopathic Epilepsy Using Valproic Acid**
Hırfanoğlu T., Serdaroğlu A., Biberoğlu G., Tümer L., Cansu A., Gücüyener K., Hasanoğlu A.
GAZI MEDICAL JOURNAL, cilt.17, sa.3, ss.0-159, 2006 (ESCI)

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

I. **Pterin Profiling in Serum, Dry Blood Spot and Urine using LC-MS/MS in Patients withHyperphenylalaninemia**
Öktem R. M., İnci A., Bayrak H., Demir F., Biberoğlu G., Mavis M. E., Okur İ., Ezgü F. S., Tümer L.
Annual Symposium 2023, Jerusalem, Yerushalayim, İsrail, 29 Ağustos 2023

II. **3-O Metil Dopa ölçümü ile AADC eksikliği taraması**
Öktem R. M., Biberoğlu G., İnci A., Okur İ., Ezgü F. S., Tümer L.
KBUD Kongre, Lab EXPO 2022, Antalya, Türkiye, 03 Ekim 2022

III. **Lysosphingolipids in the screening of sphingolipidoses**
Öktem R. M., İnci A., Biberoğlu G., Okur İ., Ezgü F. S., Tümer L.
360 LYSOSOME_FEBS Advanced Lecture Course_2022, İzmir, Türkiye, 04 Ekim 2022

IV. **Retargeting phenylbutyrate, ursodeoxycholic acid, pyrimethamine and betaine for beta-glucocerebrosidaserecovery in gaucher disease fibroblasts resulting from homozygous p.L483P mutation**
Kiliç A., BİBEROĞLU G., ÖKTEM R. M., İNCİ A., Aydogdu S., Udgu Isik B., IŞIK GÖNÜL İ., OKUR İ., TÜMER L., EZGÜ F. S.
SSIEM Annual Symposium, Almanya, 30 Ağustos - 02 Eylül 2022, sa.1418955

V. **İNFANTİL TİP POMPE HASTALIĞI ULUSAL KONSENSUS ÇALIŞMASI**
Aktaşoğlu E., İNCİ A., OKUR İ., BİBEROĞLU G., ÖKTEM R. M., EZGÜ F. S., TÜMER L., Kılıç M., Güneş S., KAĞNICI M., et al.
VII. Uluslararası Katılımlı Lizozomal Hastalıklar Kongresi, Türkiye, 25 - 27 Kasım 2021

VI. **MPS 6 Hastalarında Klinik Bulgular, ERT önce ve Sonrası Olay Bazlı Değerlendirme**
İNCİ A., OKUR İ., TÜMER L., BİBEROĞLU G., ÖKTEM R. M., EZGÜ F. S.
VII. Uluslararası Katılımlı Lizozomal Hastalıklar Kongresi, Türkiye, 25 - 27 Kasım 2021

VII. **Triamterene-induced suppression of R227X premature termination codon in Fabry disease**
Dündar H., Udgu B., Biberoğlu G., Inci A., Ezgu F. S., Işık Gönül İ., Okur İ., Tümer L.
16th Annual Research Meeting of the WORLDSymposium(TM), Florida, Amerika Birleşik Devletleri, 10 - 14 Şubat 2020, cilt.129

VIII. **Benefficial effects of Modified Atkins Diet in Glygocen Storage Disorder Type IIIa**
OLGAÇ KILIÇKAYA M. A. B., İNCİ A., OKUR İ., KASAPKARA Ç. S., BİBEROĞLU G., OĞUZ A. D., AKTAŞ E., EZGÜ F. S., TÜMER L.
SSIEM Annual Symposium 2019, Rotterdam, Hollanda, 3 - 06 Eylül 2019

IX. **Screening of twelve lysosomal storage diseases with LC-MS/MS in Gazi university hospital in Turkey: The firstresults of validation**
BİBEROĞLU G., İNCİ A., DERİN B., OKUR İ., EZGÜ F. S., TÜMER L.
SSIEM, 3 - 06 Eylül 2019

X. **Beneficial Effects of Modified Atkins Diet in Glycogen Storage Disease Type IIIa**
OLGAÇ M. A. B., İNCİ A., OKUR İ., Kasapkara Ç. S., BİBEROĞLU G., OĞUZ A. D., Aktaş E., EZGÜ F. S., TÜMER L.
SSIEM 2019, 3-6th September, 2019, Rotterdam-The Netherlands, 3 - 06 Eylül 2019

XI. **Screening of Twelve Lysosomal Storage Diseases with LC-MS/MS in Gazi University Hospital: The First Results of Validation.**
BİBEROĞLU G., İNCİ A., DERİN B., OKUR İ., EZGÜ F. S., TÜMER L.
INTERNATIONAL INBORN ERRORS OFMETABOLISM AND NUTRITION CONGRESS10 - 14 April 2019 Istanbul-Turkey, 10 - 14 Nisan 2019

XII. **Growth Hormone Treatment: Reverses Catabolic Process in Inborn Errors of Metabolism**
İNCİ A., OKUR İ., AKKUZU E., DÖĞER E., BİBEROĞLU G., KALKAN G., TÜMER L., EZGÜ F. S.
Internatıonal Inborn Errors Of Metabolism And Nutrıtıon Congress 10 - 14 April 2019, Istanbul-Turkey, 10 - 14 Nisan 2019

XIII. **Could Targeted Next Generation Sequencing Be A First Line Diagnostic Method for Lysosomal storage Diseases?**
ERGİN F. B., İNCİ A., BİBEROĞLU G., ÇİFTÇİ B., TOPÇU YÜCE A. B., TOKGÖZ D., YAZAR Ö. F., GÖKMENOĞLU H., RAJ Y., OKUR İ., et al.
INTERNATIONAL INBORN ERRORS OFMETABOLISM AND NUTRITION CONGRESS 10 - 14 April 2019 Istanbul-Turkey, Türkiye, 10 - 14 Nisan 2019

XIV. **Could Targeted Next Generation Sequencing Be A First Line Diagnostic Method for Lysosomal storage Diseases**
İNCİ A., OKUR İ., AKKUZU E., DÖĞER E., BİBEROĞLU G., KALKAN G., TÜMER L., EZGÜ F. S.
INTERNATIONAL INBORN ERRORS OFMETABOLISM AND NUTRITION CONGRESS10 - 14 April 2019 Istanbul-Turkey, 10 - 14 Nisan 2019

XV. **Respiratory system involvement of 41 Mucopolysaccaridosis patients with the evaluation of KL-6, SPA and SPD levels**
İNCİ A., OKUR İ., Yılmaz Demirtaş C., BİBEROĞLU G., ASLAN A. T., EZGÜ F. S., TÜMER L.
15 th MEMG, Beyrut, 29 Kasım - 02 Aralık 2018

XVI. **UNIQUE CLINICAL AND MOLECULAR FINDINGS IN LARGE COHORT OF PATIENTS WITH GAUCHER DISEASE FROM TURKEY**
Akay Tayfun G., OKUR İ., BİBEROĞLU G., TÜMER L., İNCİ A., Küçükcongar A., Hasanoğlu A., EZGÜ F. S.
Gaucher Symphosium, İstanbul, Türkiye, 21 - 22 Ekim 2018

XVII. **An early diagnosis cerebretendinous xanthomatosis in a patient at the age of 15 years**
İNCİ A., BİBEROĞLU G., OKUR İ., TÜMER L., EZGÜ F. S.
SSIEM, 4 - 07 Eylül 2018

XVIII. **Respiratory system involvement of mucopolysaccaridosis patients with the evaluation of KL-6, SPA and SPD levels**
İNCİ A., OKUR İ., YILMAZ-DEMİRTAŞ C., BİBEROĞLU G., aslan A. T., EZGÜ F. S., TÜMER L.
SSIEM, 4 - 07 Eylül 2018

XIX. **Sphingolipidosis : phenotypic and genotyping spectrum of patients from a single centre experience**
kılıç m., kasapkara ç. s., kabataş e., yüksel d., aksoy a., BİBEROĞLU G.
SSIEM, 4 - 07 Eylül 2018

XX. **Glycogen storage disease type 9: Insidious onset,mild form**
TÜMER L., İNCİ A., OKUR İ., BİBEROĞLU G., EZGÜ F. S.
SSIEM, 4 - 07 Eylül 2018

XXI. **The clinical evaluation of Fabry patientswith Mainz severity score index and DS3 score**
OKUR İ., İNCİ A., bütün s., BİBEROĞLU G., EZGÜ F. S., TÜMER L.
SSIEM, 4 - 07 Eylül 2018

XXII. **A new case from Turkey with glutathione synthetase deficiency complicated by necrotizing enterocolitis**
kasapkara ç. s., dinlen f., çavdarlı b., OLGAÇ M. A. B., kiliç m., BİBEROĞLU G.
SSIEM, 4 - 07 Eylül 2018

XXIII. **Determination of succinylacetone in dried blood spot: preliminary results of our laboratory**
BİBEROĞLU G., TÜMER L., OKUR İ., EZGÜ F. S., İNCİ A.
SSIEM, 4 - 07 Eylül 2018

XXIV. **The Relationship between Inflammation and Serum Estrogen, Testosterone, and Dhea-S Levels in Obstructive Coronary Artery Disease**
ÇAKMAK KARAASLAN Ö., ÜNLÜ S., TOPAL S., BİBEROĞLU G., BİBEROĞLU Ö. K., ÇENGEL A.
14th Congress of Update in Cardiology and Cardiovascular Surgery, Antalya, Türkiye, 5 - 08 Nisan 2018, cilt.121, ss.104-105

XXV. **RENAL INVOLMENT IN FABRY DİSEASE**
İNCİ A., BİBEROĞLU G., PAŞAOĞLU Ö. T., TÜMER L., PAŞAOĞLU H., EZGÜ F. S.
14 th middle east metabolic group (MEMG) meeting Athens GREECE, Atina, Yunanistan, 9 - 11 Şubat 2018

XXVI. **In Vitro Stopcodon Readthrough ofAlfa-Galactosidase and Alfa-GlucosidasePremature Termination Codons UsingGentamicin, Geneticin, and Ataluren:Therapeutic Potential for Fabry and PompeDiseases**
dundar h., BİBEROĞLU G., OKUR İ., TÜMER L., EZGÜ F. S.
ICIEM, 5 - 08 Eylül 2017

XXVII. **Renal Involvement in Fabry Disease**
İNCİ A., BİBEROĞLU G., OKUR İ., PAŞAOĞLU Ö. T., TÜMER L., PAŞAOĞLU H., EZGÜ F. S.
ICIEM, 5 - 08 Eylül 2017

XXVIII. **Short Chain Fatty Acid OxidationDefect in an Adult Patient With RefractorySeizures**
İNCİ A., TÜMER L., OKUR İ., BİBEROĞLU G., EZGÜ F. S.
ICIEM, 5 - 08 Eylül 2017

XXIX. **Screening ALPL Gene Differences byNext Generation Sequence Techonology inPatients Having Low ALP Levels**
İNCİ A., EZGÜ F. S., topcu b., çiftci b., OKUR İ., BİBEROĞLU G., TÜMER L.
ICIEM, 5 - 08 Eylül 2017

XXX. **DiagnosticCapability ofNextGenerationDNA Sequencing With A 450 Gene Panel forInborn Errors of Metabolism**
EZGÜ F. S., çiftci b., topcu b., İNCİ A., OKUR İ., BİBEROĞLU G., hasanoğlu a.
ICIEM, 5 - 08 Eylül 2017

XXXI. **Preliminary Results of Our Laboratoryfor Bile Acid Metabolism Disorders**
BİBEROĞLU G., DERİN B., İNCİ A., OKUR İ., EZGÜ F. S., TÜMER L.
ICIEM, 5 - 08 Eylül 2017

XXXII. **Carnitine Acyl Carnitine TranslocaseDeficiency With Severe Hyperammonemiaand Hypoglycemia**
İNCİ A., OKUR İ., OLGAÇ M. A. B., AKKUZU E., BİBEROĞLU G., EZGÜ F. S., TÜMER L.
ICIEM, 5 - 08 Eylül 2017

XXXIII. **Ciddi hiperammonemi ve hipoglisemi ile giden karnitin-açil translokaz olgusu**
İNCİ A., OLGAÇ KILIÇKAYA M. A. B., OKUR İ., AKKUZU E., BİBEROĞLU G., EZGÜ F. S., TÜMER L.
14. Ulusal Metabolik Hastalıklar ve Beslenme Kongresi, Muğla, Türkiye, 26 - 30 Nisan 2017

XXXIV. **In vitro translational readthrough by gentamicin and geneticin improves GLA activity in Fabry disease**
Dündar H., Biberoğlu G., Okur İ., Tümer L., Ezgü F. S.
13th Annual Research Meeting on We're Organizing Research for Lysosomal Diseases (WORLD), California, Amerika Birleşik Devletleri, 13 - 17 Şubat 2017, cilt.120

XXXV. **Evaluation of chitotriosidase and high sensitive c reactive protein levels in mucopolysaccharidosis**
İNCİ A., GENÇ B., YILMAZ-DEMİRTAŞ C., UDGU B., KARAOĞLU A., OKUR İ., EZGÜ F. S., BİBEROĞLU G., TÜMER L.
13th Middle East Metabolic Group Meeting/ Amman-Jordan, 28 - 30 Ekim 2016

XXXVI. **Evaluation of chitotriosidase and high sensitivity c reactive protein levels in mucopolysaccaridosis patients**
İNCİ A., DERİN B., YILMAZ C., udgu b., KARAOĞLU A., OKUR İ., EZGÜ F. S., BİBEROĞLU G., TÜMER L.
MEMG, 28 - 30 Ekim 2016

XXXVII. **Evaluation of chitotriosidase and high sensitive c reactive protein levels in mucopolysaccarıdosıs**
İNCİ A., GENÇ B., YILMAZ-DEMİRTAŞ C., UDGU B., KARAOĞLU A., OKUR İ., EZGÜ F. S., BİBEROĞLU G., TÜMER L.
13th MEMG Meeting, 28 ekim-30kasım 2016, Amman, Jordan, 28 - 30 Ekim 2016

XXXVIII. **Could propionylcarnitine and free carnitinebe used as antioxidative markers in mucopolysaccaridosis**
İNCİ A., BİBEROĞLU G., DERİN B., KARAOĞLU A., OKUR İ., EZGÜ F. S., TÜMER L.
MEMG, 28 - 30 Ekim 2016

XXXIX. **Do cytokine levels play a role in the pathogenesis of mucopolysaccharidosis patients**
İNCİ A., TÜMER L., YILMAZ-DEMİRTAŞ C., KARAOĞLU A., OKUR İ., OLGAÇ M. A. B., EZGÜ F. S., BİBEROĞLU G.
13th Middle East Metabolic Group Meeting/Amman -Jordan, 28 - 30 Ekim 2016

XL. **The specificity and sensitivity of next generation semiconductor DNA sequencing in detecting heteroplasmic mitochondrial**
EZGÜ F. S., topcu b., çiftci b., dündar H., BİBEROĞLU G., OKUR İ., TÜMER L.
MEMG, 28 - 30 Ekim 2016

XLI. **Evaluation of gentamycin for stop codon readthrough therapy in Fabry disease**
halil d., BİBEROĞLU G., çiftci b., topcu b., OKUR İ., TÜMER L., EZGÜ F. S.
MEMG, 28 - 30 Ekim 2016

XLII. **Early initiation of investigational enzyme replacement therapy in a nine month old infant with mucopolysaccharidosis type VII**
KARAOĞLU A., İNCİ A., BİBEROĞLU G., OKUR İ., kılıçkaya a., TÜMER L., king b., haller c., EZGÜ F. S.
MEMG, 28 - 30 Ekim 2016

XLIII. **Evaluation of chitotriosidase and high sensitivity c reactive protein levels in mucopolysaccaridosis**
İNCİ A., Genç B., Demirtaş C., Udgu B., KARAOĞLU A., OKUR İ., EZGÜ F. S., BİBEROĞLU G., TÜMER L.
SSIEM 2016: Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, Rome, Italy, 6 - 09 Eylül 2016

XLIV. **Do cytokine levels play a role in pathogenesis of mucopolysaccaridosis patients**
İNCİ A., TÜMER L., Demirtaş C., KARAOĞLU A., OKUR İ., OLGAÇ M. A. B., EZGÜ F. S., BİBEROĞLU G.
SSIEM 2016: Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, Rome, Italy, 6 - 09 Eylül 2016

XLV. **Identification of a novel mutation in Turkish infant with early onset monocarboxylate transporter 1 MCT1 deficiency as a cause of recurrent ketoacidosis**
OKUR İ., İNCİ A., KELEŞ E., KARAOĞLU A., Ceylaner S., BİBEROĞLU G., EZGÜ F. S., TÜMER L.
SSIEM 2016: Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, Rome, Italy, 6 - 09 Eylül 2016

XLVI. **Early initiation of investigational enzyme replacement therapy in a 9 month old infant with mucopolysaccharidosis type VII**
KARAOĞLU A., İNCİ A., BİBEROĞLU G., OKUR İ., Kılıçkaya A., KELEŞ E., TÜMER L., King B., Hall C., EZGÜ F. S.
SSIEM 2016: Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, Rome, Italy, 6 - 09 Eylül 2016

XLVII. **Identification of a novel mutation in Turkish infant with early onset monocarboxylatetransporter1 MCT1 deficiencyasacauseofrecurrent ketoacidosi**
OKUR İ., İNCİ A., KELEŞ E., KARAOĞLU A., CEYLANER S., BİBEROĞLU G., EZGÜ F. S., TÜMER L.
SSIEM 2016: Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, Rome, Italy, 6 - 09 Eylül 2016, cilt.39, ss.35-284

XLVIII. **Plasma acylcarnitine levels Are there New İnflammatory markers in lysosomal storage disease**
BİBEROĞLU G., DERİN B., İNCİ A., udgu b., kurnaz p., OKUR İ., EZGÜ F. S., TÜMER L.
MEMG, 29 Ekim - 01 Kasım 2015

XLIX. **Is there any effect of acylcarnitines on proinflammatory process in obese children**
BİBEROĞLU G., DERİN B., İNCİ A., DÖĞER E., OKUR İ., EZGÜ F. S., TÜMER L.
SSIEM, 1 - 04 Eylül 2015

L. **A novel mutation for L 2 hydroxyglutaric aciduria in a 7 year old patient**
OLGAÇ M. A. B., TÜMER L., EZGÜ F. S., BİBEROĞLU G., alev h.
SSIEM, 1 - 04 Eylül 2015

LI. **Mucopolysaccharidosis Type VII at an Early Age A good candidate for investigational enzyme replacement therapy**
Abdulbaki K., EZGÜ F. S., BİBEROĞLU G., OLGAÇ M. A. B., İNCİ A., TÜMER L.
SSIEM, 1 - 04 Eylül 2015

LII. **A completely new approach to the diagnosis of inbornerrors development of a 450 gene all metabolic disorders next generation sequencing panel**
EZGÜ F. S., çiftçi b., topçu b., OKUR İ., İNCİ A., OLGAÇ M. A. B., KARAOĞLU A., BİBEROĞLU G., TÜMER L., hasanoğlu a.
SSIEM Annual Symposium, 1 - 04 Eylül 2015

LIII. **Lysinuric protein intolerance An overlooked diagnosis**
TÜMER L., OLGAÇ M. A. B., ÖZGÜL R. K., YENİCESU İ., EZGÜ F. S., BİBEROĞLU G., hasanoğlu a.
SSIEM Annual Symposium, 1 - 04 Eylül 2015

LIV. **The results of enzyme studies in the diagnosis of lysosomal diseases: 8 years experience of Gazi University, Ankara, Turkey**
Hasanoglu A., BİBEROĞLU G., OKUR İ., Turner L., EZGÜ F. S., Udgu B., Olgac A.
11th Annual WORLD Symposium of the Lysosomal-Disease-Network, Florida, Amerika Birleşik Devletleri, 9 - 13 Şubat 2015, cilt.114

LV. **Isovaleric acidemia and Niemann Pick disease type C coexistence and new mutation for Niemann Pick disease type C**
TÜMER L., Olgac A., BİBEROĞLU G., SARI S., DALGIÇ B., Hasanoglu A.
11th Annual WORLD Symposium of the Lysosomal-Disease-Network, Florida, Amerika Birleşik Devletleri, 9 - 13 Şubat 2015, cilt.114

LVI. **Identification of novel mutations and prevalence for Fabry disease (FD) via screening studies using dried blood samples (DBS) among hemodialysis patients in Turkey**
Okura I., BİBEROĞLU G., EZGÜ F. S., Turner L., ERTEN Y., Bicik Z., Akin Y., Ecder T., Hasanoglu A.
11th Annual WORLD Symposium of the Lysosomal-Disease-Network, Florida, Amerika Birleşik Devletleri, 9 - 13 Şubat 2015, cilt.114

LVII. **Importance of family screening in Fabry disease: Reaching the bottom of the iceberg**
Ezgu F. S., Koca S., OKUR İ., BİBEROĞLU G., TÜMER L., Bakkaloglu S. A., ERTEN Y., Hasanoglu A.
11th Annual WORLD Symposium of the Lysosomal-Disease-Network, Florida, Amerika Birleşik Devletleri, 9 - 13 Şubat 2015, cilt.114

LVIII. **PREVALENCE OF FABRY DISEASE AMONG HEMODIALYSIS PATIENTS IN TURKEY**
Okur İ., BİBEROĞLU G., Ezgu F. S., TÜMER L., Hasanoglu A., Bicik Z., Akin Y., Mumcuoglu M., Ecder T.
50th European-Renal-Association - European-Dialysis-and-Transplant-Association Congress, İstanbul, Türkiye, 18 - 21 Mayıs 2013, cilt.28, ss.321

Desteklenen Projeler

BİBEROĞLU G., Yükseköğretim Kurumları Destekli Proje, Büyüme Hormonu Tedavisi Alan Çocuklarda Serbest ve Açilkarnitin Düzeyleri, 2004 - 2006

BİBEROĞLU G., Yükseköğretim Kurumları Destekli Proje, Çocukluk çağı kanserlerinde L-propionil karnitin düzeyleri, 2002 - 2004

BİBEROĞLU G., Yükseköğretim Kurumları Destekli Proje, Amino asit metabolizması bozukluklarının Tandem Mass spektrometre ile taranması, 2000 - 2002

BİBEROĞLU G., Yükseköğretim Kurumları Destekli Proje, Juvenil diabette antioksidasyon mekanizmasında yer alan

enzimler ve Se düzeyi, 1993 - 1993
BİBEROĞLU G., Yükseköğretim Kurumları Destekli Proje, Peroksizomal hastalıklarda çok uzun zincirli yağ asitlerinin HPLC ile tayini, 1993 - 1993

Metrikler

Yayın: 112
Atıf (WoS): 241
Atıf (Scopus): 272
H-İndeks (WoS): 9
H-İndeks (Scopus): 10